{
  "meta": {
    "title": "Sle",
    "url": "https://brainandscalpel.vercel.app/sle-c6bbaafb.html",
    "scrapedAt": "2025-11-30T11:13:20.710Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">Anti-dsDNA antibody - rash, liver disease</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">Anti-Ro antibody- heart block</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">Anti-Smith antibody- glomerulonephritis</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">ANA antibody- skin rash</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A Female with SLE becomes pregnant. Which of the following antibodies is responsible for the below shown life-threatening manifestation in the fetus?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025091527d48331-1bae-4f1d-b3fd-e8089cc01d06.png\"></span></p>",
      "unique_key": "DT1197613",
      "question_audio": null,
      "question_video": null,
      "map_id": 1197613,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>This question addresses a classic complication of <strong>neonatal lupus</strong>, which occurs due to passive transplacental transfer of maternal autoantibodies, particularly <strong>anti-Ro (SSA)</strong> and <strong>anti-La (SSB)</strong>.</li>\n<li>The most feared and <strong>life-threatening complication</strong> is <strong>congenital heart block</strong>, a result of damage to the fetal cardiac conduction system, especially the <strong>atrioventricular (AV) node</strong>. This damage leads to <strong>third-degree AV block</strong>, as seen in the provided fetal ECG image (prolonged PR interval, atrial and ventricular dissociation).</li>\n<li>Importantly, <strong>anti-Ro antibody is the strongest serologic predictor</strong> of congenital complete heart block. This manifestation is independent of whether the mother has active lupus symptoms.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Anti-dsDNA antibody (Option A): </strong>While associated with <strong>lupus nephritis</strong> and overall disease activity in SLE, it is <strong>not linked to congenital heart block</strong>.</p>\n<p><strong>Anti-Sm antibody (Option C):</strong> This antibody is specific for SLE but <strong>not predictive of fetal complications</strong> like congenital heart block.</p>\n<p><strong>ANA antibody (Option D):</strong> Though present in most patients with SLE, ANA is <strong>non-specific</strong> and does not correlate with neonatal lupus or congenital heart manifestations.</p>",
      "correct_choice_id": 2,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">Anti-ribosomal p antibody</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">Anti-neuronal antibody</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">Anti-C1q antibody</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">Anti-RNP antibody</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Besides Anti-ds DNA, which antibody is reflective of disease activity in SLE, although it is not very specific?</span></p>",
      "unique_key": "DT1197641",
      "question_audio": null,
      "question_video": null,
      "map_id": 1197641,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li><strong>Anti-C1q antibodies</strong> are not specific or highly sensitive for SLE overall. However, they are <strong>strongly associated with active lupus nephritis</strong>.</li>\n<li>The levels of anti-C1q antibodies tend to <strong>fluctuate with disease activity</strong>, particularly reflecting <strong>renal flare-ups</strong>.</li>\n<li>Hence, although not specific, they can serve as a <strong>useful marker for monitoring disease activity</strong> in patients with lupus nephritis.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Anti-ribosomal P antibody (Option A):</strong> Associated with <strong>neuropsychiatric manifestations</strong> of SLE, such as psychosis and mood disorders. Not a reliable marker for overall disease activity.</p>\n<p><strong>Anti-neuronal antibody (Option B):</strong> Seen in SLE patients with <strong>CNS involvement</strong>, but lacks clinical utility for monitoring disease activity.</p>\n<p><strong>Anti-RNP antibody (Option D):</strong> Primarily associated with <strong>mixed connective tissue disease (MCTD)</strong>, and not a reliable marker of disease activity in isolated SLE.</p>",
      "correct_choice_id": 13,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">Anti-Ro (SSA) antibody will be seen in the maternal serum</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">Complete heart block of the fetus can be reversed with Dexamethasone</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">HCQ should be given to mothers with a previous history of CHB in the fetus</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">Structural heart disease can also be associated with anti-Ro antibodies</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 27-year-old patient with systemic lupus erythematosus attends the obstetric clinic at 25 weeks into her pregnancy. The fetal heart rate is 45 beats per minute. Foetal echocardiography shows complete heart block. Which one of the following is false?</span></p>",
      "unique_key": "DT1197650",
      "question_audio": null,
      "question_video": null,
      "map_id": 1197650,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li><strong>Complete heart block</strong>, once developed, always requires <strong>pacing</strong>.</li>\n<li><strong>Dexamethasone</strong> is given to the mother for <strong>first and second-degree heart block in the fetus</strong>, so that progression to CHB is prevented.</li>\n</ul>\n<p>NEONATAL LUPUS:</p>\n<ul>\n<li><strong>Congenital heart block</strong> with or without cardiomyopathy- life-threatening</li>\n<li>Vigilant monitoring of heart rate in <strong>Ro antibody-positive mothers</strong>.</li>\n<li><strong>Anti-Ro/SSA antibodies </strong>are commonly found in mothers whose fetuses develop CHB. They <strong>cross the placenta and damage the fetal conduction system. (Option A)</strong></li>\n<li><strong>HCQ</strong> treatment of an <strong>anti-Ro-positive mother</strong> reduces the chance that subsequent fetuses will develop heart block. <strong>(Option C)</strong></li>\n<li>No treatment for heart block. Dexamethasone(and not prednisolone, since fluorinated steroids cross the placenta) treatment of a mother in whom fetal first- or second-degree heart block is detected <strong>only prevents progression</strong>to complete heart block.</li>\n<li><strong>Structural heart diseases like ASD, VSD, PDA, and PFO</strong> can be seen with neonatal lupus. <strong>(Option D)</strong></li>\n<li>Rash is similar to subacute cutaneous lupus.</li>\n</ul>",
      "correct_choice_id": 22,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Drug-induced lupus, Anti-histone antibody</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Systemic Lupus Erythematosus, Anti-histone antibody</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">Drug-induced lupus, Anti-Smith antibody</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">Systemic Lupus Erythematosus, Anti-Smith antibody</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 19-year-old girl presents with a 6-week history of pain in multiple joints with early morning stiffness. Her symptoms responded well initially to Ibuprofen but then they worsened again. She has no other systemic symptoms. She had been taking Minocycline for her acne. Investigations show: ESR 140 mm/hr, CRP 110 mg/l, Rheumatoid Factor negative, ANA strongly positive (1:1600), showing a homogeneous (diffuse) immunofluorescence pattern on indirect immunofluorescence. What is the most probable diagnosis and the most likely associated antibody?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025091588f5cfb8-bbba-4ff5-81d2-fc82c21256e0.png\"></span></p>",
      "unique_key": "DT1197610",
      "question_audio": null,
      "question_video": null,
      "map_id": 1197610,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>The question deals with <strong>inflammatory arthritis</strong>(joint pain with stiffness) in a female of reproductive age.</li>\n<li>A <strong>raised ESR, CRP</strong> also point towards an inflammatory cause. The <strong>most common cause of inflammatory arthritis</strong> in females of reproductive age is</li>\n<li>If we look more into the details given, it is said that she is on <strong>Minocycline</strong>, which is implicated in drug-induced lupus. So it is not simple SLE, but <strong>drug-induced lupus(DIL).</strong></li>\n<li>The <strong>homogeneous ANA pattern</strong> is most often associated with <strong>anti-histone antibodies</strong>.</li>\n</ul>\n<p><strong>Drug induced Lupus(DIL):</strong></p>\n<ul>\n<li><strong>Positive ANA</strong></li>\n<li><strong>Fever, malaise, arthritis or intense arthralgias/myalgias, serositis, and/ or rash.</strong></li>\n<li>Rarely involving the kidney and brain.</li>\n<li>Associated with <strong>anti-histone antibodies.</strong></li>\n<li>It resolves over weeks after discontinuation of medications.</li>\n<li>Asymptomatic ANA positivity is also seen on exposure to the drugs.</li>\n<li>SHIP Pnemonic may be used to remember a few. S- Sulfasalazine, H-Hydralazine, I-Isoniazid, P-Procainamide, P-Phenytoin</li>\n<li>TNF alpha inhibitors can also cause this.</li>\n<li>The incidence of Drug-Induced Lupus is less in females and more in whites.</li>\n</ul>\n<p><strong>Common drugs that can cause lupus.</strong></p>\n<p>Hydrochlorothiazide, Angiotensin-converting enzyme inhibitors, beta blockers, Propylthiouracil, lithium, phenytoin, isoniazid, minocycline, nitrofurantoin, sulfasalazine, lovastatin and simvastatin.</p>\n<p><strong>Patterns of staining in IF:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250915aa8ef3bd-7a93-4197-824a-4db1c24ca7a7.png\">\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Systemic lupus erythematosus, Anti-histone antibody (Option B): </strong>While anti-histone antibodies may be seen in SLE, they are <strong>not the most specific</strong> marker. Anti-dsDNA and anti-Sm are more commonly associated with idiopathic SLE. In this clinical context of drug exposure and lack of systemic features, this is less likely.</p>\n<p><strong>Drug-induced lupus, Anti-Sm antibody (Option C): </strong>Anti-Sm antibodies are <strong>highly specific for idiopathic SLE</strong>, not drug-induced lupus. Their presence in DIL is extremely rare.</p>\n<p><strong>Systemic lupus erythematosus, Anti-Sm antibody (Option D): </strong>Although this combination is typical in idiopathic SLE, the history of drug use (minocycline), absence of systemic signs, and strong homogeneous ANA pattern favour DIL.</p>",
      "correct_choice_id": 31,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Erythromycin</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">Isotretinoin</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">Minocycline</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">Oxytetracycline</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 26-year-old woman has acne and is taking oral medication. She develops polyarthritis and has raised liver enzyme tests. Investigations show: AST 95 U/l (A-3D- ALT 170 U/l (5-35) Bilirubin 0.6 mg/dl Antinuclear antibodies: Strongly positive at 1/20 Negative at 1/640 Which of the following drugs is she most likely to have been prescribed?</span></p>",
      "unique_key": "DT1197648",
      "question_audio": null,
      "question_video": null,
      "map_id": 1197648,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<p>All other drugs listed above are used in the treatment of acne.</p>\n<p>Among the given options,</p>\n<ul>\n<li><strong>ANA positivity with autoimmune hepatitis</strong>is seen with <strong>Minocycline</strong>. Other drugs which produce the same profile are <strong>Alpha methyl dopa, Hydralazine, and nitrofurantoin</strong>.</li>\n<li>These agents <strong>cause autoimmune hepatitis</strong> with anti-LKM2 positivity.</li>\n<li><strong>Erythromycin</strong> causes cholestatic jaundice and not hepatitis, and is not associated with ANA. <strong>(Option A ruled out)</strong></li>\n<li><strong>Oxytetracycline</strong> causes fatty liver and photosensitivity. <strong>(Option D ruled out)</strong></li>\n<li><strong>Isotretinoin</strong> is associated with neutropenia and headaches as the common side effects, but hepatitis and arthritis are very rare, and ANA positivity has not been described. <strong>(Option B ruled out)</strong></li>\n<li>Usually Drug drug-induced lupus is <strong>anti-dsDNA negative. But anti-dsDNA is positive with DIL caused by Minocycline and TNF inhibitors.</strong></li>\n<li><strong>Anti-histone is not specific for DIL, as it may be positive in 85% of idiopathic SLE.</strong></li>\n</ul>",
      "correct_choice_id": 43,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">Anti-dsDNA and serum Complement levels</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">ESR</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">CRP</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">ANA</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">What are the parameters that you use in a patient with SLE for assessing the disease activity?</span></p>",
      "unique_key": "DT1231907",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231907,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<p><strong>Anti-dsDNA antibody titers</strong> and <strong>serum complement levels (C3/C4)</strong> are the most reliable markers for <strong>monitoring disease activity in SLE</strong>, especially during flares.</p>\n<ul>\n<li>A <strong>rise in anti-dsDNA levels</strong> or a <strong>fall in complement levels</strong> typically correlates with disease activity, especially renal involvement.</li>\n<li><strong>ESR</strong> and <strong>CRP</strong> are nonspecific; ESR may be elevated in active disease, but CRP usually rises only during <strong>infection or serositis</strong>, making them unreliable as sole disease activity markers.</li>\n<li><strong>ANA</strong>, though highly sensitive, is not specific and does not correlate with activity-it remains positive irrespective of disease activity.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>ESR (Option B):</strong> Nonspecific marker. It can be elevated during active lupus or any inflammatory state (e.g., infections), so it <strong>cannot reliably distinguish between flare and infection</strong>.</p>\n<p><strong>CRP (Option C):</strong> Usually normal in lupus flares unless there is <strong>infection</strong> or <strong>serositis</strong>. Hence, not a dependable marker for disease activity alone.</p>\n<p><strong>ANA (Option D):</strong> Useful for diagnosis (very sensitive) but <strong>not for monitoring</strong>, as it usually remains <strong>persistently positive</strong> in most patients with SLE.</p>",
      "correct_choice_id": 51,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">The most common symptom complex of SLE is musculoskeletal</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Most arthritis in SLE is erosive on XRAY</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">The most common acute cutaneous lesion is a butterfly rash</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">The most frequent haematological manifestation is anaemia</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is an incorrect statement for SLE?</span></p>",
      "unique_key": "DT1197640",
      "question_audio": null,
      "question_video": null,
      "map_id": 1197640,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>SLE most commonly presents with <strong>musculoskeletal involvement (Option A)</strong>, especially <strong>arthritis and arthralgia</strong>.</li>\n<li>However, unlike <strong>rheumatoid arthritis (RA)</strong>, the <strong>arthritis of SLE</strong> is characteristically <strong>non-erosive</strong>, even in longstanding disease.</li>\n<li>Imaging studies like X-rays typically do <strong>not</strong> show joint erosions in SLE patients.</li>\n<li>The <strong>malar or butterfly rash</strong> is the most classic <strong>acute cutaneous manifestation</strong> of SLE and is seen in a significant proportion of patients<strong> (Option C).</strong></li>\n<li><strong>Anaemia</strong> is the most frequent haematological finding in SLE and may be due to chronic disease, renal involvement, or autoimmune haemolysis. <strong>(Option D)</strong></li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250915c8baea5e-20eb-4020-a071-83e7e2f220c4.PNG\">",
      "correct_choice_id": 62,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">Libman- Sacks Endocarditis</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">Bacterial Endocarditis</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">Fungal Endocarditis</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">Non-Bacterial Thrombotic Endocarditis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">What is the characteristic lesion that can be seen in the heart valves of a patient with SLE?</span></p>",
      "unique_key": "DT1231890",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231890,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>The <strong>hallmark valvular lesion in SLE</strong> is <strong>Libman-Sacks endocarditis</strong>, which is characterised by <strong>sterile verrucous vegetations</strong>. These vegetations:\n<ul>\n<li>They are composed of <strong>immune complexes, mononuclear cells, fibrin, and platelet thrombi</strong></li>\n<li>Most commonly affect the <strong>mitral and aortic valves</strong></li>\n<li>May occur on <strong>either side of the leaflet,</strong> and even on the endocardial surface</li>\n<li>It can lead to valve dysfunction in some cases. This lesion is <strong>non-infective</strong> and pathognomonic of SLE-related cardiac involvement.</li>\n</ul>\n</li>\n<li>Libman-Sacks endocarditis is more likely in <strong>active lupus</strong> and <strong>antiphospholipid antibody syndrome (APLS)</strong></li>\n<li>May present asymptomatically or with symptoms of <strong>valvular regurgitation</strong></li>\n<li>Detected by <strong>transesophageal echocardiography (TEE).</strong></li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/2024033095104f08-ab69-4002-972b-d8bfee24a576.jpg\">\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Bacterial Endocarditis (Option B):</strong> Caused by microbial infection with positive blood cultures and fever; vegetations are friable and destructive, unlike sterile vegetations in SLE.</p>\n<p><strong>Fungal Endocarditis (Option C): </strong>Occurs in immunocompromised or prosthetic valve patients; rare in SLE and characterised by large vegetations with risk of embolisation<strong>.</strong></p>\n<p><strong>Non-bacterial Thrombotic Endocarditis (Option D): </strong>Seen in malignancy or hypercoagulable states, but differs from Libman-Sacks by being less inflammatory and not associated with SLE.</p>",
      "correct_choice_id": 71,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">1 and 3</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">2 and 4</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 2 and 3</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">All of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following statements are true regarding SLE?<br>1. Hip joint pain in a patient who is on treatment for SLE should raise suspicion of ischemic bone necrosis.<br>2. Leucopenia in SLE predisposes to life threatening infections<br>3. Thrombocytopenia in SLE is a recurrent problem<br>4. The most common ocular manifestation is Optic neuritis</span></p>",
      "unique_key": "DT1231877",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231877,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>This question deals with the <strong>non-life-threatening symptoms of SLE</strong>.</li>\n<li>The most common is Musculoskeletal (95%), followed by Haematological (85%)</li>\n<li><strong>Monoarthritis of large joints in patients with SLE&rarr; suspect Ischemic necrosis of bone due to steroids</strong></li>\n<li>Myopathy can be a manifestation of disease, or a complication of steroids or HCQ</li>\n<li>The most common haematological manifestation is anaemia.</li>\n<li>The most common cause of anaemia is chronic inflammation.</li>\n<li>Autoimmune haemolytic anaemia is also seen.</li>\n<li><strong>Leukopenia</strong> and lymphocytopenia are seen, <strong>but they do not predispose to infections. (Statement 2 is false)</strong></li>\n<li><strong>Thrombocytopenia</strong> is seen. It is usually <strong>recurrent</strong>. The first few episodes respond to steroids. Rituximab or platelet growth factors, or splenectomy in refractory cases</li>\n<li>The <strong>most common ocular manifestation is SICCA</strong> syndrome and non-specific conjunctivitis. Vision-threatening diseases include retinal vasculitis and optic neuritis. <strong>(Statement 4 is false)</strong></li>\n</ul>",
      "correct_choice_id": 81,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">NSIP</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">UIP</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">Tuberculosis</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">PAH</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient who is a known case of systemic lupus erythematosus (SLE) now presents with a history of dry cough and exertional dyspnoea. The HRCT image of the patient is given below. Which of the following is the anticipated complication of SLE depicted in the image?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250915e51d78d9-5594-46af-83b4-de5d7a802cef.png\"></span></p>",
      "unique_key": "DT1231881",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231881,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>This patient is suffering from <strong>interstitial lung disease (ILD)</strong>, which is a known pulmonary complication of SLE.</li>\n<li>Among ILD subtypes, <strong>Non-Specific Interstitial Pneumonitis (NSIP)</strong> is the most common pattern seen in SLE patients.</li>\n</ul>\n<p><strong>NSIP presents with:</strong></p>\n<ul>\n<li><strong>Ground-glass</strong> opacities</li>\n<li>Subpleural sparing</li>\n<li>Reticular abnormalities</li>\n<li>Minimal or absent <strong>honeycombing</strong><br /> It is best diagnosed via <strong>HRCT thorax</strong>, which is the investigation of choice for evaluating suspected interstitial lung disease.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>UIP (Option B):</strong> Usual interstitial pneumonia is the most common ILD pattern seen in idiopathic pulmonary fibrosis, not SLE. It shows basal-predominant honeycombing and traction bronchiectasis.</p>\n<p><strong>Tuberculosis (Option C):</strong> Though patients with SLE are immunocompromised and at higher risk for TB, the chronic interstitial changes on HRCT here are more suggestive of ILD, not infectious aetiology.</p>\n<p><strong>PAH (Option D):</strong> Pulmonary arterial hypertension can occur in SLE but presents with dyspnoea and right heart strain on ECHO, not with interstitial infiltrates on HRCT.</p>",
      "correct_choice_id": 91,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 2 and 3</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 3 and 5</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 3, 4 and 5</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">All of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is true regarding life threatening manifestations of SLE?<br>1. Cognitive dysfunction is the most common neurological manifestation.<br>2. Vaso occlusion in SLE is closely related to the presence of anti phospholipid antibodies.<br>3. Increased ALT and AST are seen during disease flares.<br>4. Nausea, vomiting and diarrhoea are common during disease flares.<br>5. Head ache and psychosis can occur due to complication of treatment for SLE\r\n</span></p>",
      "unique_key": "DT1231883",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231883,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li><strong>Neurological manifestations</strong> (seen in 60% of patients): May be due to vasoocclusion or primary neurological disease like cognitive dysfunction, headache, seizure and psychosis.</li>\n<li><strong>Headache and psychosis can occur as a complication of treatment with steroids</strong>.</li>\n<li><strong>Vasoocclusive features</strong> ( seen in 15%): The Risk of vasoocclusion is high in people with SLE and is <strong>not related to the presence of APLA. (Statement 2 is false)</strong></li>\n<li><strong>Pulmonary features </strong>(seen in60%):\n<ul>\n<li>MC is pleurisy</li>\n<li>Life-threatening conditions are pulmonary haemorrhage and interstitial fibrosis</li>\n</ul>\n</li>\n<li><strong>Cardiac features</strong> (seen in 60%):\n<ul>\n<li>Pericarditis is the most common manifestation. Life-threatening conditions are myocarditis and endocarditis</li>\n</ul>\n</li>\n<li><strong>Gastrointestinal symptoms (Seen in 40%): nausea, vomiting and diarrhoea and raised liver enzymes are common with lupus flare.</strong></li>\n<li>Life-threatening complications include peritonitis and mesenteric ischemia.</li>\n</ul>",
      "correct_choice_id": 103,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">All are true</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 3 and 4</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">1 and 3</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">1 and 4</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is true regarding the treatment of SLE?<br>1. Arthritis can be well controlled with NSAIDS or HCQS<br>2. Refractory lupus dermatitis can be treated with Dapsone, thalidomide or Lenalidomide.<br>3. Life or organ threatening manifestations in SLE requires aggressive immunosuppression with High dose glucocorticoids along with either MMF or Cyclophosphamide.<br>4. HUS in SLE is managed by plasma exchange.</span></p>",
      "unique_key": "DT1231885",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231885,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<p><strong>Arthritis management</strong>:</p>\n<ul>\n<li>1<sup>st</sup>line: <strong>NSAIDS and HCQ</strong>. Dehydroepiandosterone in mild disease</li>\n<li>2<sup>nd</sup>line: Low dose steroids, Belimumab(anti baff), Anifrolumab ( anti TNF)</li>\n</ul>\n<p><strong>Dermatitis management</strong>:</p>\n<ul>\n<li>1<sup>st</sup>line: Topical sunscreen, hydroxychloroquine, topical steroids,</li>\n<li>2<sup>nd</sup>line: MMF, Azathioprine, Methotrexate, Belimumab, Anifrolumab is highly effective.</li>\n</ul>\n<p><strong>Refractory</strong>: topical tacrolimus with systemic <strong>Dapsone, tacrolimus or lenalidomide</strong>.</p>\n<p><strong>For life/organ-threatening disease</strong>:</p>\n<ul>\n<li><strong>High-dose Glucocorticoid with MMF/ Cyclophosphamide.</strong></li>\n<li>Followed by maintenance with MMF and Azathioprine.</li>\n<li>With persistent response, taper off all drugs.</li>\n</ul>\n<p><strong>For</strong> <strong>HUS/TTP:</strong></p>\n<ul>\n<li>Plasma exchange</li>\n</ul>\n<p><strong>All statements are true.</strong></p>",
      "correct_choice_id": 111,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">Methotrexate</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">Prednisolone</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">Azathioprine</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">Hydroxychloroquine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 20-year-old female with systemic lupus erythematosus has arthralgia involving her upper limbs. She also has a butterfly facial rash and a rash on the trunk. Urine dipstick shows no Proteinuria or haematuria. Her renal function is normal. Which one of the following medications is most appropriate as the front-line therapy?</span></p>",
      "unique_key": "DT1197623",
      "question_audio": null,
      "question_video": null,
      "map_id": 1197623,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Our patient is having non-life-threatening symptoms.</li>\n<li><strong>Hydroxychloroquine</strong> is the first-line drug that can be given for both <strong>rash and arthritis. </strong></li>\n<li>NSAIDs can also be given to this patient. Hence, the most appropriate answer is <strong>hydroxychloroquine</strong>.</li>\n<li>Hydroxychloroquine is well tolerated and <strong>reduces flares</strong>, especially in patients with mild disease. In contrast, immunosuppressants and corticosteroids are typically reserved for <strong>moderate-to-severe or organ-threatening</strong> manifestations of SLE.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Methotrexate (Option A):</strong> Primarily used for <strong>inflammatory arthritis</strong> such as rheumatoid arthritis; used in SLE for severe arthritis, but not as first-line therapy in mild disease.</p>\n<p><strong>Prednisolone (Option B):</strong> Although effective, corticosteroids are generally reserved for <strong>flare control</strong> or <strong>organ involvement</strong>. Long-term use is associated with significant adverse effects and is not preferred first-line treatment in mild disease.</p>\n<p><strong>Azathioprine (Option C):</strong> An <strong>immunosuppressive agent</strong> reserved for moderate to severe manifestations such as <strong>lupus nephritis</strong> or systemic symptoms. Not indicated in mild, cutaneous-joint-limited disease.</p>",
      "correct_choice_id": 124,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">Class II - Mesangial hypercellularity with deposits, hypertension</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">Class III - Focal segmental or global proliferative GN, nephrotic syndrome</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">Class IV - Diffuse proliferative GN, renal failure</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">Class V - Membranous GN with wire loop lesions, thrombosis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A known patient of systemic lupus erythematosus (SLE) presents with new-onset proteinuria. A renal biopsy is performed, which reveals diffuse proliferative glomerulonephritis. Which of the following stages of SLE does the biopsy specify, and what is the specific complication associated with this stage?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGMCQ/20250822ced48426-0f2c-4b08-b61c-f4e137ece354.jpg\"></span></p>",
      "unique_key": "DT1197634",
      "question_audio": null,
      "question_video": null,
      "map_id": 1197634,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li><strong>Class IV lupus nephritis</strong>, also known as <strong>diffuse proliferative glomerulonephritis</strong>, is the most common and severe form of lupus nephritis.</li>\n<li>It involves <strong>&ge;50% of glomeruli</strong> and typically presents with:\n<ul>\n<li>Heavy <strong>proteinuria</strong></li>\n<li><strong>Hematuria</strong></li>\n<li><strong>Active urinary sediment</strong></li>\n<li>Progression to <strong>renal failure</strong> if not treated aggressively</li>\n</ul>\n</li>\n<li>Histologic findings include <strong>endocapillary proliferation</strong>, <strong>subendothelial immune complex deposition</strong>, and <strong>wire loop lesions</strong>.</li>\n<li>This class carries the highest risk of progression to <strong>end-stage renal disease (ESRD)</strong>, making <strong>renal failure</strong> its most specific and feared complication.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509157ced4670-3eba-425f-8f02-79e8906e0558.PNG\">",
      "correct_choice_id": 133,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">All are correct</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 2 and 3</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 3 and 5</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 2 and 4</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following statements are true regarding the management of Lupus nephritis?<br> 1. HCQS should be included as treatment for all classes since it reduces the accrual of tissue damage. <br>2. Management of Class I and Class II should be guided by the extra renal manifestations.<br> 3. Class III and IV require aggressive immunosuppression. <br>4. Isolated Class V has got better prognosis than Class IV.<br> 5. Isolated class V without nephrotic range proteinuria requires only supportive</span></p>",
      "unique_key": "DT1231913",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231913,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The question deals with the <strong>management and prognosis of Lupus Nephritis. </strong></p>\n<ul>\n<li><strong>HCQ should be in the management of all classes of lupus nephritis. </strong></li>\n<li><strong>Class I and II should be treated</strong> mainly based on the <strong>extra-renal manifestations</strong>.</li>\n<li><strong>Class III and IV</strong> are the proliferative and serious forms and <strong>require aggressive immunosuppression</strong> with high-dose glucocorticoid with either MMF or Cyclophosphamide.</li>\n<li><strong>Isolated Class V presents with proteinuria alone and has got better outcome than Class IV.</strong> But class V often coexists with class III and IV. Class V with nephrotic range proteinuria should be treated with immunosuppression, usually steroids with calcineurin inhibitors.</li>\n<li><strong>Isolated class V</strong> without nephrotic range proteinuria requires only <strong>supportive management.</strong></li>\n</ul>\n<p><strong>All statements are true.</strong></p>",
      "correct_choice_id": 141,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16,
      "choices": [
        {
          "id": 151,
          "text": "<p><span style=\"font-size:12.0pt;\">All are true</span></p>"
        },
        {
          "id": 152,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 3 and 4</span></p>"
        },
        {
          "id": 153,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 2 and 3</span></p>"
        },
        {
          "id": 154,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 2 and 4</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 15-year-old female who is diagnosed with SLE has come to your OP for review. Which of the following statements is true?<br> 1. Permanent remission is seen only in <5% individuals. <br> 2. The aim of treatment is disease remission on treatment or Low Lupus Disease Activity. <br> 3. Anti-dsDNA or C3 levels are used as markers of disease flare <br> 4. SLEDAI 2k score of >3 indicates active disease.</span></p>",
      "unique_key": "DT1231887",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231887,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<p>The question deals with <strong>treatment endpoints in SLE</strong>.</p>\n<ul>\n<li>Complete <strong>permanent remission</strong>(no disease activity without any treatment) is seen in <strong>&lt;5%.</strong></li>\n<li><strong>The aim of treatment</strong> in SLE is <strong>disease remission on treatment or low-level disease activity.</strong></li>\n<li>Disease activity is measured using the SLEDAI 2k score, and a score of &gt; 4 indicates an active disease.</li>\n<li><strong>Anti-DS DNA titres and C3 complement levels</strong> are used as <strong>markers of disease flare</strong>.</li>\n<li>SLEDAI-2K score <strong>&gt;3</strong> is <strong>not sufficient alone</strong> to define active disease unless supported by other clinical features; active disease is usually considered at a <strong>score &ge;6</strong> in most clinical trials. <strong>(Statement 4 is false</strong>)</li>\n</ul>",
      "correct_choice_id": 153,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17,
      "choices": [
        {
          "id": 161,
          "text": "<p><span style=\"font-size:12.0pt;\">Anti-Ro antibody</span></p>"
        },
        {
          "id": 162,
          "text": "<p><span style=\"font-size:12.0pt;\">Anti-GBM antibody</span></p>"
        },
        {
          "id": 163,
          "text": "<p><span style=\"font-size:12.0pt;\">Anti-cardiolipin antibody</span></p>"
        },
        {
          "id": 164,
          "text": "<p><span style=\"font-size:12.0pt;\">ASOT</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 40-year-old woman presents with left flank pain. On examination she was febrile, had livedo reticularis and a blood pressure of 190/100 mmHg. She has also had a history of a butterfly rash in the past.<br>Investigations revealed:<br>Hb 13.9 g/dL<br>WBC 6.5 x 10^9/L<br>Platelet count 110 x 10^9/L<br>Serum Creatinine 0.9 mg/dL<br>Urine dipstick analysis: blood ++, protein -<br>Which one of the following tests is likely to be positive?</span></p>",
      "unique_key": "DT1197653",
      "question_audio": null,
      "question_video": null,
      "map_id": 1197653,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>This patient shows signs of <strong>antiphospholipid antibody syndrome (APLS)</strong>, which frequently coexists with SLE. The key features supporting this diagnosis are:\n<ul>\n<li><strong>Hypertension and hematuria</strong> without significant proteinuria</li>\n<li><strong>Livedo reticularis</strong> (classic skin finding in APLS)</li>\n<li><strong>Recurrent pregnancy loss</strong> (a hallmark criterion for APLS)</li>\n</ul>\n</li>\n<li><strong>Anti-cardiolipin antibodies</strong> are one of the three antiphospholipid antibodies used to diagnose APLS. These antibodies can cause both arterial and venous thrombosis and pregnancy-related complications.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Anti-Ro antibody (Option A):</strong> Seen in SLE, especially subacute cutaneous lupus or neonatal lupus, but not specifically associated with pregnancy loss or thrombotic events.</p>\n<p><strong>Anti-GBM antibody (Option B):</strong> Seen in Goodpasture syndrome. It causes rapidly progressive glomerulonephritis with pulmonary haemorrhage, not related to livedo or pregnancy loss.</p>\n<p><strong>ASOT (Option D):</strong> Antistreptolysin O titer is used to detect recent <strong>Streptococcal infections</strong>, and has no relevance in SLE or APLS.</p>",
      "correct_choice_id": 163,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18,
      "choices": [
        {
          "id": 171,
          "text": "<p><span style=\"font-size:12.0pt;\">1 and 3</span></p>"
        },
        {
          "id": 172,
          "text": "<p><span style=\"font-size:12.0pt;\">1 and 4</span></p>"
        },
        {
          "id": 173,
          "text": "<p><span style=\"font-size:12.0pt;\">2 and 4</span></p>"
        },
        {
          "id": 174,
          "text": "<p><span style=\"font-size:12.0pt;\">2,4 and 5</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 26-year-old female who is planning to conceive has come to you for advice. She has a history of stroke 6 years back and was diagnosed with Antiphospholipid Syndrome and is on Warfarin. Which of the following statements is incorrect?<br> 1. Warfarin has to be stopped before a planned pregnancy as it is teratogenic.<br> 2. The patient has to be started only on a prophylactic dose of heparin as it is her first pregnancy. <br>3. The patient has to be started on a therapeutic dose of heparin as she gives a history of thrombosis in the past. <br>4. Newer oral anticoagulants are approved for the treatment of APS.<br> 5. With anticoagulation, the risk of IUGR decreases substantially.</span></p>",
      "unique_key": "DT1231888",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231888,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<p>This question deals with the recommendations for <strong>anticoagulation in Antiphospholipid Syndrome (APS).</strong></p>\n<p><strong>Statement 1:</strong> It is a known fact that <strong>Warfarin is teratogenic</strong>, which makes <strong>statement  1 true.</strong></p>\n<p><strong>Statements 2 and 3</strong>: These statements deal with recommendations for anticoagulation in pregnancy in patients with APS.</p>\n<ul>\n<li>Patients who have had a <strong>previous history of thrombosis due to APS</strong>, <strong>regardless of their previous pregnancy morbidity</strong>, should receive a <strong>therapeutic dose</strong>(1mg/kg LMWH twice daily) of heparin and warfarin postpartum that has to be <strong>continued lifelong.</strong></li>\n<li>In patients with APS <strong>and previous pregnancy morbidity( defined as &ge; 1 fetal loss or &ge; 3 embryonic loss), but no history of thrombosis prophylactic dose of heparin( 0.5mg/kg LMWH once daily) should be given with low-dose aspirin, throughout pregnancy and continued 4-6 weeks postpartum.</strong></li>\n<li>In patients with diagnosed APS and a first pregnancy, no treatment is required.</li>\n</ul>\n<p>So <strong>statement 2 is incorrect, and statement 3 is correct.</strong></p>\n<p><strong>Statement 4:</strong> <strong>DOACs are not recommended</strong> in the <strong>treatment of APS,</strong> and hence it is incorrect.</p>\n<p><strong>Statement 5:</strong> <strong>Even with therapeutic anticoagulation, IUGR can occur in APS;</strong> hence, it is wrong</p>\n<p>So <strong>statements 2, 4 and 5 are wrong.</strong></p>\n<p><strong>Treatment of APS in general</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250915d5492691-8b76-4bc3-969c-6f434e660159.PNG\">",
      "correct_choice_id": 174,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19,
      "choices": [
        {
          "id": 181,
          "text": "<p><span style=\"font-size:12.0pt;\">It is safe to continue both prednisolone and HCQs</span></p>"
        },
        {
          "id": 182,
          "text": "<p><span style=\"font-size:12.0pt;\">Prednisolone has to be changed to Dexamethasone, HCQS is safe and may be continued</span></p>"
        },
        {
          "id": 183,
          "text": "<p><span style=\"font-size:12.0pt;\">Prednisolone is safe and can be continued, but HCQS has to be stopped</span></p>"
        },
        {
          "id": 184,
          "text": "<p><span style=\"font-size:12.0pt;\">No need to continue treatment as the disease is well controlled</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 26-year-old patient who is a known case of SLE is coming to you with a positive UPT. She is on 5mg prednisolone and 200 mg HCQ daily, and her disease is well controlled. What advice will you give her?</span></p>",
      "unique_key": "DT1231889",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231889,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>In patients with SLE who become pregnant, <strong>continuing immunomodulatory therapy is essential</strong> to avoid flare-ups and reduce fetal complications.</li>\n<li><strong>Prednisolone</strong> is the preferred steroid in pregnancy. It is <strong>inactivated by 11&beta;-hydroxysteroid dehydrogenase in the placenta</strong>, preventing fetal exposure.</li>\n<li><strong>Hydroxychloroquine (HCQ)</strong> is <strong>FDA-approved for use in pregnancy</strong> and is shown to <strong>reduce disease activity and prevent flares</strong> in pregnant SLE patients.</li>\n<li>Discontinuing treatment may increase the risk of <strong>SLE flares, fetal loss, lupus nephritis, and hypertensive complications</strong>.</li>\n<li>Therefore, <strong>both drugs should be continued during pregnancy</strong> if the disease is controlled.</li>\n</ul>\n<p><strong>Drugs used in the treatment of SLE in pregnancy:</strong></p>\n<p><strong>First-line agents</strong>: prednisone, prednisolone, HCQ</p>\n<p><strong>Second line agents</strong>: Azathioprine. (May cause fetal harm)</p>\n<p>Breastfeeding is contraindicated with immunosuppressants</p>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Prednisolone has to be changed to Dexamethasone, HCQ is safe and may be continued (Option B):</strong> Dexamethasone is <strong>not preferred during pregnancy</strong> because it is <strong>not inactivated by the placenta</strong>, thus exposing the fetus to steroids.</p>\n<p><strong>Prednisolone is safe and can be continued, but HCQ has to be stopped (Option C):</strong>  HCQ is <strong>safe and essential</strong> in SLE during pregnancy.</p>\n<p><strong>No need to continue treatment as the disease is well controlled (Option D):</strong> <strong>Discontinuing therapy increases the risk</strong> of flares and complications during pregnancy. </p>",
      "correct_choice_id": 181,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}